Literature DB >> 17624587

The role of cyclooxygenase-2 in breast cancer: review.

Gurpreet Singh-Ranger1, Mohamed Salhab, Kefah Mokbel.   

Abstract

There is a growing body of evidence that COX-2 expression s a fundamental step in breast cancer pathogenesis acting through prostaglandin-dependent and independent mechanisms. Epidemiological studies suggest that NSAIDs confer a moderate degree of benefit against breast cancer. However further work is required to establish how this enzyme system can be best manipulated for therapeutic benefit.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17624587     DOI： 10.1007/s10549-007-9641-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  49 in total

1.  Noninvasive imaging identifies new roles for cyclooxygenase-2 in choline and lipid metabolism of human breast cancer cells.

Authors:  Tariq Shah; Ioannis Stasinopoulos; Flonne Wildes; Samata Kakkad; Dmitri Artemov; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2011-09-22       Impact factor: 4.044

Review 2.  Integrin α3β1 as a breast cancer target.

Authors:  Sita Subbaram; C Michael Dipersio
Journal:  Expert Opin Ther Targets       Date:  2011-08-13       Impact factor: 6.902

3.  Impact of cyclooxygenase-2 over-expression on the prognosis of breast cancer patients.

Authors:  Sertaç Ata Güler; Mustafa Ümit Uğurlu; Handan Kaya; Semiha Şen; Yasemin Nazlı; Bahadır M Güllüoğlu
Journal:  Ulus Cerrahi Derg       Date:  2015-06-01

Review 4.  ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta       Date:  2012-03-08

5.  Integrin α3β1 controls mRNA splicing that determines Cox-2 mRNA stability in breast cancer cells.

Authors:  Sita Subbaram; Scott P Lyons; Kimberly B Svenson; Sean L Hammond; Lorena G McCabe; Sridar V Chittur; C Michael DiPersio
Journal:  J Cell Sci       Date:  2014-01-16       Impact factor: 5.285

6.  Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.

Authors:  Anne-Sophie Hamy; Sandrine Tury; Xiaofei Wang; Junheng Gao; Jean-Yves Pierga; Sylvie Giacchetti; Etienne Brain; Barbara Pistilli; Michel Marty; Marc Espié; Gabriel Benchimol; Enora Laas; Marick Laé; Bernard Asselain; Brice Aouchiche; Martin Edelman; Fabien Reyal
Journal:  J Clin Oncol       Date:  2019-01-31       Impact factor: 44.544

7.  Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial.

Authors:  Patricia A Thompson; Chiu-Hsieh Hsu; Sylvan Green; Alison T Stopeck; Karen Johnson; David S Alberts; H-H Sherry Chow
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

8.  Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast.

Authors:  Min Hu; Guillermo Peluffo; Haiyan Chen; Rebecca Gelman; Stuart Schnitt; Kornelia Polyak
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-13       Impact factor: 11.205

9.  Functional interaction between acyl-CoA synthetase 4, lipooxygenases and cyclooxygenase-2 in the aggressive phenotype of breast cancer cells.

Authors:  Paula M Maloberti; Alejandra B Duarte; Ulises D Orlando; María E Pasqualini; Angela R Solano; Carlos López-Otín; Ernesto J Podestá
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

10.  In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

Authors:  Anne E Lykkesfeldt; Katrine L Henriksen; Birgitte B Rasmussen; Hironobu Sasano; Dean B Evans; Susanne Møller; Bent Ejlertsen; Henning T Mouridsen
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.